Absci gained on animal testing phaseout news, but the change has limited near-term impact on its investment case. Read why ...

Absci Corp. is the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins. It partners with pharma and biotech ...

Needham highlighted Absci's distinct approach in the competitive artificial intelligence ... shows the company maintains a strong liquidity position with a current ratio of 5.63 and holds more ...

Ratings for Absci ABSI were provided by 7 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The following table encapsulates their recent ratings ...

VANCOUVER, Wash. and NEW YORK, April 14, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will report ...

KeyBanc raised the firm’s price target on Absci (ABSI) to $9 from $5 and keeps an Overweight rating on the shares. Into Q1 earnings, the firm believes the focus for the HCIT sector will be on ...

Pre-earnings options volume in AbSci (ABSI) Corp is normal with calls leading puts 8:3. Implied volatility suggests the market is anticipating a move near 16.5%, or 51c, after results are released.

Absci management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss its business developments, financial and operating results ...

ABSCI ($ABSI) posted quarterly earnings results on Tuesday, March 18th. The company reported earnings of -$0.25 per share, missing estimates of -$0.24 by $0.01. The ...

Absci Corp (NASDAQ:ABSI) is set to release its Q4 2024 earnings on Mar 18, 2025. The consensus estimate for Q4 2024 revenue is $3.48 million, and the earnings are expected to come in at -$0.21 per ...